The estimated Net Worth of James Engelhart is at least $3.25 Million dollars as of 6 January 2022. Mr. Engelhart owns over 7,000 units of Biohaven Ltd stock worth over $605,525 and over the last 8 years he sold BHVN stock worth over $85,100. In addition, he makes $2,560,770 as Chief Financial Officer and Treasurer at Biohaven Ltd.
Sign up
Mr. Engelhart BHVN stock SEC Form 4 insiders trading
James has made over 14 trades of the Biohaven Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of BHVN stock worth $250,040 on 6 January 2022.
The largest trade he's ever made was exercising 73,725 units of Biohaven Ltd stock on 10 June 2020 worth over $440,876. On average, James trades about 10,231 units every 95 days since 2017. As of 6 January 2022 he still owns at least 16,952 units of Biohaven Ltd stock.
You can see the complete history of Mr. Engelhart stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Engelhart biography
James Engelhart serves as Chief Financial Officer, Treasurer of Biohaven Pharmaceutical Holding Company Limited. Prior to this, from August 2014 to May 2016, he served as executive director of finance, Americas for Alexion Pharmaceuticals, Inc., and from March 2006 to July 2014, he served as a finance director for Energizer Holdings, Inc. From May 1998 to March 2006, Mr. Engelhart served in increasingly senior finance roles for BMS and held finance roles in R&D Operations and International Operations at Schering-Plough from 1992 to 1998. Mr. Engelhart currently serves on the board of directors of OLM School of Madison. Mr. Engelhart started his career as an auditor with Coopers & Lybrand LLP from 1986 through 1991. Mr. Engelhart received his B.S. in accounting from Villanova University and is a CPA (inactive).
What is the salary of James Engelhart?
As the Chief Financial Officer and Treasurer of Biohaven Ltd, the total compensation of James Engelhart at Biohaven Ltd is $2,560,770. There are 4 executives at Biohaven Ltd getting paid more, with Vlad Coric having the highest compensation of $6,787,630.
How old is James Engelhart?
James Engelhart is 56, he's been the Chief Financial Officer and Treasurer of Biohaven Ltd since 2016. There are 8 older and 7 younger executives at Biohaven Ltd. The oldest executive at Biohaven Ltd is Julia Gregory, 67, who is the Independent Director.
What's James Engelhart's mailing address?
James's mailing address filed with the SEC is C/O BIOHAVEN PHARMACEUTICALS, INC., 215 CHURCH STREET, NEW HAVEN, CT, 06510.
Insiders trading at Biohaven Ltd
Over the last 8 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs, and Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.
What does Biohaven Ltd's logo look like?
Complete history of Mr. Engelhart stock trades at Biohaven Ltd
Biohaven Ltd executives and stock owners
Biohaven Ltd executives and other stock owners filed with the SEC include:
-
Vlad Coric,
Chief Executive Officer, Director -
William Jones,
Chief Commercial Officer, Migraine and Common Diseases -
Charles Conway,
Chief Scientific Officer -
Kimberly Gentile,
Senior Vice President - Clinical Operations -
James Engelhart,
Chief Financial Officer, Treasurer -
Elyse Stock,
Chief Medical Officer -
John Tilton,
Chief Commercial Officer, Rare and Orphan Diseases -
Dr. Vladimir Coric M.D.,
Chairman, CEO & Pres -
William Jones M.B.A.,
Chief Commercial Officer of Migraine & Common Diseases -
Julia Gregory,
Independent Director -
John Childs,
Director -
Gregory Bailey,
Director -
Dr. Elyse Stock M.D.,
Chief Medical Officer -
Kimberly Gentile,
Sr. VP of Clinical Operations -
Robert Berman,
Lead - Special Projects and Medical Oversight -
Robert Hugin,
Director -
Michael Heffernan,
Director -
Thomas Lynch,
Chairman of the Board -
Clifford Bechtold M.S.,
Pres & GM of Biohaven Ireland and Chief Compliance Officer -
Wendy Goss,
Exec. Admin. Assistant -
Dr. Charles Conway,
Chief Scientific Officer -
George C. Clark,
VP & Chief Accounting Officer -
Matthew DeLawder,
Director of Accounting -
Matthew Buten,
Chief Financial Officer -
Albert Cha,
Director -
Robert Repella,
Director -
Eric Aguiar,
-
Biotech Inc. Portage,
-
Declan Doogan,
-
Irina Antonijevic,
-
Kishan Mehta,
-
George C. Clark,
VP, Chief Accounting Officer -
Matthew Buten,
Chief Financial Officer -
Pharmaceutical Holding Co L...,
-
Bruce Car,
Chief Scientific Officer